乙型肝炎肝硬化患者外周血T细胞亚群变化

doi:10.3969/j.issn.1672-5069.2020.06.040

Abstract

Wu Liexiu, Duan Chunmiao, Li Zhaohui. Peripheral blood T lymphocyte subset changes in patients with hepatitis B liver cirrhosis[J]. Journal of Practical Hepatology, 2020, 23(6): 917-918.

[1] 朱翔,韩凌飞,杨燕,等.病毒性肝炎患者外周血T细胞亚群与病毒载量、胃蛋白酶原水平及胃黏膜病变程度的相关研究.中国免疫学杂志,2020,36(1):84-89.
[2] Griebel P, Ma Q, Dong X, et al. Hepatitis B eantigen induces NKG2A(+) natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus infection. Hum Vaccin Immunother, 2020, 8(13): 421.
[3] Kim J H, Ghosh A, Ayithan N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients.Sci Rep, 2020, 10(1): 1835.
[4] 李铃, 敬雪明, 朱其荣, 等. 乙肝病毒感染后不同临床类型及HBV DNA载量与外周血T细胞亚群变化的相关性分析. 中国现代医学杂志, 2015,25(17):35-41.
[5] 柴艳云, 李建国, 金磊. 乙型肝炎肝硬化患者外周血补体和T淋巴细胞计数的变化. 实用肝脏病杂志, 2016,19(6):724-725.
[7] Abbasi A, Peeke S, Shah N, et al. Axicabta gene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. J Hematol Oncol, 2020, 13(1): 1.
[8] 吕辉, 郝世勇. 乙型肝炎肝硬化患者血细胞参数的变化及意义. 临床血液学杂志:输血与检验, 2015, 28(1):115-117.
[9] De Beijer M T A, Jansen D, Dou Y, et al. Discovery and selection of hepatitis B virus-derived T cell epitopes for global immunotherapy based on viral indispensability, conservation, and HLA-binding strength. J Virol, 2020, 94(7):322-325.
[10] Cheng LS, Liu Y, Jiang W. Restoring homeostasis of CD4⁺ T cells in hepatitis B virus related liver fibrosis.World J Gastroenterol,2015,21(38): 10721-10731.
[11] Whitacre D C, Peters C J, Sureau C, et al. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother, 2020, 16(2): 251-268.
[12] Wu J, Niu Q, Yuan J, et al. lncRNA-CD160 decreases the immunity of CD8(+) T cells through epigenetic mechanisms in hepatitis B virus infection. Oncol Lett, 2020, 20(1): 235-247.
[13] Zawawi A, Forman R. In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection. Hum Vaccin Immunother, 2020, 16(3): e1008243.

[1]	Song Jinyun, Wang Jianfang, Zhao Hongyu. Hepatitis B viralgenotypes in patients with chronic hepatitis B and cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(1): 87-90.
[2]	Wei Rongrong, Li Ailing, Li Hong, et al. Changes and clinical significance of indocyanine green clearance test in patients with chronic viral hepatitis, liver cirrhosis and liver failure [J]. Journal of Practical Hepatology, 2021, 24(1): 91-94.
[3]	Zhang Xin, Guo Yue, Yang Jun. Evaluation ofesophageal and gastric varices by liver and splenic stiffness measurement by elastography in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(1): 95-98.
[4]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.
[5]	Ye Xiaoting,Sun Qingfeng,Fu Rongquan, et al. Clinical efficacy of tenofovir and Fuzhenghuayu capsule in treatment of patients with chronic hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(1): 143-144.
[6]	Sun Hao, Zhu Guijuan, Chen Xiaoyu. Total liver volume/spleen volume ratio by multislice CT calculation in diagnosis of patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(6): 837-840.
[7]	Diao Qing, Duan Yinhuan, Miao Liang, et al. Efficacy and safety of direct acting antiviral agents in the treatment of patients with hepatitis C cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(6): 841-844.
[8]	Li Cuiru, Wu Li, Ping Caiyan, et al. Clinical efficacy of microecological agents in the treatment of patients with hepatitis B liver cirrhosis complicated by spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2020, 23(6): 845-848.
[9]	Feng Kai, Guo Aihua, Huang Lu, et al. Clinical study of endoscopic tissue gel injection and sclerotherapy-ligation in the treatment of cirrhotic patients with esophageal and gastric varices [J]. Journal of Practical Hepatology, 2020, 23(6): 849-852.
[10]	Wu Ronggang, Zhang Biquan, Wang Zhen. Value of CT-detected portal parameters in the diagnosis of significant clinical portal hypertension and predicting variceal bleeding in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(6): 853-856.
[11]	Liu Hui, Zhang Yifeng, Yu Lei. Application of terlipressin and somatostatincombination in treatment of cirrhotic patients with upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2020, 23(6): 857-860.
[12]	Pan Hongduo, Dang Tong, Zhou Yi, et al. Terlipressin in combination with albumin infusion for patients with cirrhosis and type Ⅱ hepatorenal syndrome [J]. Journal of Practical Hepatology, 2020, 23(6): 861-864.
[13]	Song Lijun, Lu Xuehong, Xue Zhiwei, et al. Diagnostic value of three-dimensional reconstruction of blood vessels by CT scan in differential diagnosis of patients with Budd Chiari syndrome and liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(6): 865-868.
[14]	Zeng Yanni, Han Jun, Liu Liangjin, et al.. CT liver perfusion imaging parameters in patients with schistosomiasis-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(5): 691-694.
[15]	Yang Xi, Song Dongmei, Hua Min.. Efficacy and impact on blood coagulation functions of somatostatin and octreotide combination in the treatment of cirrhotic patients with upper gastrointestinal hemorrhage [J]. Journal of Practical Hepatology, 2020, 23(5): 695-698.

Peripheral blood T lymphocyte subset changes in patients with hepatitis B liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments